Four Houston scientists named rising stars in research

who to watch

These four Houstonians are among the best researchers in the state. Image via Getty Images

Four Houston scientists were named among a total of five Texas rising stars in research by the Texas Academy of Medicine, Engineering, Science & Technology, or TAMEST, last month.

The group will be honored at the 2023 Edith and Peter O’Donnell Awards by TAMEST in May. According to Edith and Peter O’Donnell Committee Chair Ann Beal Salamone, the researchers "epitomize the Texas can-do spirit."

The Houston winners include:

Medicine: Dr. Jennifer Wargo

A physician and professor of surgical oncology and genomic medicine at The University of Texas MD Anderson Cancer Center, Wargo was named a 2023 honoree for her discoveries surrounding the "important connection between treatment outcomes and a patient’s gut microbiome," according to a statement from TAMEST.

Engineering: Jamie Padgett

The Stanley C. Moore Professor of Engineering at Rice University, Padgett was honored for her work that aims to "enhance reliability and improve the sustainability of critical community infrastructure" through developing new methods for multi-hazard resilience modeling.

Physical sciences: Erez Lieberman Aiden

As a world-leading biophysical scientist and an associate professor of molecular and human genetics at Baylor College of Medicine, is being honored for his work that has "dramatically impacting the understanding of genomic 3D structures." He is working with BCM to apply his findings to clinical settings, with the hope that it will eventually be used to treat disease by targeting dark matter in the body.

Technology innovation: Chengbo Li

As a geophysicist at ConocoPhillips, Li is being recognized for innovations in industry-leading Compressive Seismic Imaging (CSI) technology. "This CSI technology allows the oil and gas industry to produce these seismic surveys in less time, with less shots and receivers, and most importantly, with less of an environmental impact," his nominator Jie Zhang, founder and chief scientist of GeoTomo LLC, said in a statement.


James J. Collins III at UT Southwestern Medical Center in Dallas was also named this year's rising star in the biological sciences category for his research on schistosomiasis, a disease that impacts some of the world’s poorest individuals.

The O'Donnell Awards have granted more than $1.5 million to more than 70 recipients since they were founded in 2006. Each award includes a $25,000 honorarium and an invitation to present at TAMEST’s Annual Conference each year, according to TAMEST's website.

The awards expanded in 2002 to include both a physical and biological sciences award each year, thanks to a $1.15 million gift from the O’Donnell Foundation in 2022.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston edtech company closes oversubscribed $3M seed round

fresh funding

Houston-based edtech company TrueLeap Inc. closed an oversubscribed seed round last month.

The $3.3 million round was led by Joe Swinbank Family Limited Partnership, a venture capital firm based in Houston. Gamper Ventures, another Houston firm, also participated with additional strategic partners.

TrueLeap reports that the funding will support the large-scale rollout of its "edge AI, integrated learning systems and last-mile broadband across underserved communities."

“The last mile is where most digital transformation efforts break down,” Sandip Bordoloi, CEO and president of TrueLeap, said in a news release. “TrueLeap was built to operate where bandwidth is limited, power is unreliable, and institutions need real systems—not pilots. This round allows us to scale infrastructure that actually works on the ground.”

True Leap works to address the digital divide in education through its AI-powered education, workforce systems and digital services that are designed for underserved and low-connectivity communities.

The company has created infrastructure in Africa, India and rural America. Just this week, it announced an agreement with the City of Kinshasa in the Democratic Republic of Congo to deploy a digital twin platform for its public education system that will allow provincial leaders to manage enrollment, staffing, infrastructure and performance with live data.

“What sets TrueLeap apart is their infrastructure mindset,” Joe Swinbank, General Partner at Joe Swinbank Family Limited Partnership, added in the news release. “They are building the physical and digital rails that allow entire ecosystems to function. The convergence of edge compute, connectivity, and services makes this a compelling global infrastructure opportunity.”

TrueLeap was founded by Bordoloi and Sunny Zhang and developed out of Born Global Ventures, a Houston venture studio focused on advancing immigrant-founded technology. It closed an oversubscribed pre-seed in 2024.

Texas space co. takes giant step toward lunar excavator deployment

Out of this world

Lunar exploration and development are currently hampered by the fact that the moon is largely devoid of necessary infrastructure, like spaceports. Such amenities need to be constructed remotely by autonomous vehicles, and making effective devices that can survive the harsh lunar surface long enough to complete construction projects is daunting.

Enter San Antonio-based Astroport Space Technologies. Founded in San Antonio in 2020, the company has become a major part of building plans beyond Earth, via its prototype excavator, and in early February, it completed an important field test of its new lunar excavator.

The new excavator is designed to function with California-based Astrolab's Flexible Logistics and Exploration (FLEX) rover, a highly modular vehicle that will perform a variety of functions on the surface of the moon.

In a recent demo, the Astroport prototype excavator successfully integrated with FLEX and proceeded to dig in a simulated lunar surface. The excavator collected an average of 207 lbs (94kg) of regolith (lunar surface dust) in just 3.5 minutes. It will need that speed to move the estimated 3,723 tons (3,378 tonnes) of regolith needed for a lunar spaceport.

After the successful test, both Astroport and Astrolab expressed confidence that the excavator was ready for deployment. "Leading with this successful excavator demo proves that our technology is no longer theoretical—it is operational," said Sam Ximenes, CEO of Astroport.

"This is the first of many implements in development that will turn Astrolab's FLEX rover into the 'Swiss Army Knife' of lunar construction. To meet the infrastructure needs of the emerging lunar economy, we must build the 'Port' before the 'Ship' arrives. By leveraging the FLEX platform, we are providing the Space Force, NASA, and commercial partners with a 'Shovel-Ready' construction capability to secure the lunar high ground."

"We are excited to provide the mobility backbone for Astroport's groundbreaking construction technology," said Jaret Matthews, CEO of Astrolab, in a release. "Astrolab is dedicated to establishing a viable lunar ecosystem. By combining our FLEX rover's versatility with Astroport's civil engineering expertise, we are delivering the essential capabilities required for a sustainable lunar economy."

---

This article originally appeared on CultureMap.com.

Houston biotech co. raises $11M to advance ALS drug development

drug money

Houston-based clinical-stage biotechnology company Coya Therapeutics (NASDAQ: COYA) has raised $11.1 million in a private investment round.

India-based pharmaceuticals company Dr. Reddy’s Laboratories Inc. led the round with a $10 million investment, according to a news release. New York-based investment firm Greenlight Capital, Coya’s largest institutional shareholder, contributed $1.1 million.

The funding was raised through a definitive securities purchase agreement for the purchase and sale of more than 2.5 million shares of Coya's common stock in a private placement at $4.40 per share.

Coya reports that it plans to use the proceeds to scale up manufacturing of low-dose interleukin-2 (IL-2), which is a component of its COYA 302 and will support the commercial readiness of the drug. COYA 302 enhances anti-inflammatory T cell function and suppresses harmful immune activity for treatment of Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), Parkinson’s disease and Alzheimer’s disease.

The company received FDA acceptance for its investigational new drug application for COYA 302 for treating ALS and FTD this summer. Its ALSTARS Phase 2 clinical trial for ALS treatment launched this fall in the U.S. and Canada and has begun enrolling and dosing patients. Coya CEO Arun Swaminathan said in a letter to investors that the company also plans to advance its clinical programs for the drug for FTD therapy in 2026.

Coya was founded in 2021. The company merged with Nicoya Health Inc. in 2020 and raised $10 million in its series A the same year. It closed its IPO in January 2023 for more than $15 million. Its therapeutics uses innovative work from Houston Methodist's Dr. Stanley H. Appel.

View All Listings